HAFC
Banks - Regional · Financial Services
Equibles does not estimate personal net worth.
Get an email with a short summary when Hanmi Financial Corp publishes a filing, an earnings call transcript or a press release.
Get HAFC alertsEarlier roles on record: CFO at Marker Therapeutics, Inc. (MRKR) until September 30, 2022. Marker Therapeutics, Inc. reported in an 8-K filed September 27, 2022 that Anthony Kim was terminated as Chief Financial Officer, effective September 30, 2022. The proxy statement of Hanmi Financial Corp reports total compensation of $670,511 for Anthony Kim in fiscal 2023, including a base salary of $348,693. Disclosed compensation is on record for 5 fiscal years. Anthony Kim has spoken on 6 earnings calls and 1 other investor event across 2 companies, most recently for Hanmi Financial Corp on October 27, 2026. Those appearances were for Hanmi Financial Corp (HAFC) and Marker Therapeutics, Inc. (MRKR). Hanmi Financial Corp is classified in the Banks - Regional industry within the Financial Services sector. Other companies whose calls Anthony Kim spoke on are classified in the Healthcare sector. Other leadership on record at Hanmi Financial Corp includes Bonita I. Lee (CEO and Board Member), C. G. Kum (CEO), Joseph A. Pangrazio (Chief Accounting Officer) and 7 others.
“the Company had separated Anthony Kim, Chief Financial Officer of the Company, effective September 30, 2022, as part of the Company's capital conservation measures.”
“I'll begin by providing additional details on our loan productions. Third quarter loan production was $544 million, up $172 million, or 46.2%, from the prior quarter, with a weighted average interest rate of 6.61%, compared to 6.59% last quarter.”
“I'll begin by providing additional details on our loan production. Second quarter loan production was $372 million, down $6 million, or 1.6% from the prior quarter, with a weighted average interest rate of 6.59% compared to 6.54% last quarter.”
“I will begin by providing additional details on our loan production. Second quarter loan production was $372 million, down $6 million or 1.6% from the prior quarter with a weighted average interest rate of 6.59% compared to 6.54% last quarter.”
“I'll begin by providing additional details on our loan production. First quarter loan production was $378 million, up $3 million, or 0.8% from the prior quarter, with a weighted average interest rate of 6.54% compared to 6.90% last quarter.”
“I will begin by providing additional details on our loan production. Fourth-quarter loan production was $375 million, down $196 million, or 34%, from the prior quarter, with a weighted average interest rate of 6.90%, compared to 6.91% last quarter.”
Source not stated
Start not stated–2022-09-30
HAFC
Banks - Regional · Financial Services
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Hanmi Financial Corp (HAFC) | Sr. EVP & CBO | $348,693 | $670,511 |
| 2022 | Marker Therapeutics, Inc. (MRKR) | Former Chief Financial Officer | $330,370 | $929,170 |
| 2022 | Hanmi Financial Corp (HAFC) | Sr. EVP & CBO | $313,154 | $638,997 |
| 2021 | Marker Therapeutics, Inc. (MRKR) | Former Chief Financial Officer | $400,754 | $948,291 |
| 2021 | Hanmi Financial Corp (HAFC) | Sr. EVP & CBO | $291,158 | $569,575 |
| 2020 | Marker Therapeutics, Inc. (MRKR) | Chief Financial Officer | $392,906 | $829,306 |
| 2020 | Hanmi Financial Corp (HAFC) | EVP & CBO | $277,432 | $423,314 |
| 2019 | Marker Therapeutics, Inc. (MRKR) | Chief Financial Officer | $375,000 | $431,523 |